iShares Biotechnology ETF (NASDAQ:IBB) Hits New 52-Week High – Here’s Why

iShares Biotechnology ETF (NASDAQ:IBB) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as $179.64 and last traded at $179.52, with a volume of 853627 shares trading hands. The stock had previously closed at $177.00.

iShares Biotechnology ETF Price Performance

The business has a 50-day moving average of $170.71 and a 200 day moving average of $170.72.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Monday, June 15th were paid a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date was Monday, June 15th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Darwin Wealth Management LLC purchased a new position in iShares Biotechnology ETF during the 2nd quarter worth $25,000. Basepoint Wealth LLC purchased a new stake in iShares Biotechnology ETF in the fourth quarter worth $26,000. Cary Street Partners Financial LLC bought a new stake in iShares Biotechnology ETF in the 4th quarter valued at about $29,000. Copia Wealth Management bought a new position in iShares Biotechnology ETF during the fourth quarter worth about $34,000. Finally, Caitlin John LLC bought a new position in iShares Biotechnology ETF during the fourth quarter worth about $34,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.